WORLD PEPTIDEFOUNDATION

Where is Mazdutide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Mazdutide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

GLP-1/glucagon receptor agonist

Mazdutide

Mazdutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic disease. Weight-management and type 2 diabetes trials have different enrolled populations, regimens, comparators, and endpoints.

Record status

Traceability partial

Last meaningful update: 9/26/2026

Evidence searched through:
Not recorded
Assessment updated:
9/26/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
None recorded
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

51

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

25

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

13

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

28

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

51

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

25

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

13

Independent evidence dossiers covering the major research questions.

Published source records

28

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

13 published domain syntheses connected to 25 featured studies

Mazdutide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record28 governed records · titles, provenance, and original-source linksOpen records ↓
2026Phase 3 human evidence

Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.

Content-verified record concerning Mazdutide: "Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial." Abstract excerpt: Effective weight management and glycemic control are both important in people with type 2 diabetes (T2D) and obesity. Despite the proven benefits of GLP-1 receptor agonists, there is a persistent need for more effective weight management strategies in the treatment of T2D and obesity. Glucagon receptor-based co-agonists, such as mazdutide, represent a promising therapeutic class with the potential

Source
peer_reviewed_research
DOI
10.1016/j.cct.2025.108150
PubMed
41260459
Open original source
2024Phase 1–2 human evidence

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Content-verified record concerning Mazdutide: "Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial." Abstract excerpt: We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, a once-weekly glucagon-like peptide 1 and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes. Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol

Source
peer_reviewed_research
DOI
10.2337/dc23-1287
PubMed
37943529
Open original source
2025Phase 1–2 human evidence

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

Content-verified record concerning Mazdutide: "Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial." Abstract excerpt: Mazdutide, an agonist of glucagon-like peptide-1 and glucagon receptors, significantly reduced weight in early phase trials at doses up to 10 mg. This randomized, double-blind, placebo-controlled Phase 1 trial evaluated the safety and efficacy of mazdutide up to 16 mg in adults with overweight or obesity. Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous

Source
peer_reviewed_research
DOI
10.1111/dom.70040
PubMed
40832785
Open original source
2024Phase 1–2 human evidence

Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.

Content-verified record concerning Mazdutide: "Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1097/mjt.0000000000001756
PubMed
39292847
Open original source
2023Phase 1–2 human evidence

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

Content-verified record concerning Mazdutide: "A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity." Abstract excerpt: Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-part (low doses up to 6 mg and high dose of 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT0490

Source
peer_reviewed_research
DOI
10.1038/s41467-023-44067-4
PubMed
38092790
Open original source
2022Phase 1–2 human evidence

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

Content-verified record concerning Mazdutide: "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial." Abstract excerpt: Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss up to 6.4% at doses up to 6 mg in Chinese adults with overweight or obesity. We further explored the safety and efficacy of mazdutide dosed up to 9 mg and 10 mg. In this randomised, placebo-controlled, multiple-ascending-dose phase

Source
peer_reviewed_research
DOI
10.1016/j.eclinm.2022.101691
PubMed
36247927
Open original source
2026Phase 1–2 human evidence

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial.

Content-verified record concerning Mazdutide: "Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial." Abstract excerpt: Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity. In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body m

Source
peer_reviewed_research
DOI
10.1016/j.medj.2026.101063
PubMed
41875890
Open original source
2026Phase 1–2 human evidence

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

Content-verified record concerning Mazdutide: "Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial." Abstract excerpt: Obesity is a worldwide problem and a major public health issue in China. To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of ≥30). A double-blind, placebo-controlled, phase 3, randomized clinical trial including Chinese adults with or without type 2 diabete

Source
peer_reviewed_research
DOI
10.1001/jama.2026.8142
PubMed
42251595
Open original source
2026Phase 1–2 human evidence

Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

Content-verified record concerning Mazdutide: "Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial." Abstract excerpt: Therapies targeting GLP-1 or glucose-dependent insulinotropic polypeptide (GIP) receptors have provided efficacious weight reduction in adults with obesity. Mazdutide, a glucagon and GLP-1 receptor dual agonist, presents a novel opportunity for differentiated weight reduction. We aimed to evaluate the efficacy, safety, and tolerability of once-weekly mazdutide across a dose range up to 16 mg in ad

Source
peer_reviewed_research
DOI
10.1016/s2213-8587(26)00160-9
PubMed
42628555
Open original source
2026Phase 1–2 human evidence

Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

Content-verified record concerning Mazdutide: "Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials." Abstract excerpt: Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity. A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity. Meta-analysis was performed using RevMa

Source
peer_reviewed_research
DOI
10.1111/dom.70643
PubMed
41804840
Open original source
2025Observational human evidence

Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.

Content-verified record concerning Mazdutide: "Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia." Abstract excerpt: Mazdutide, a glucagon-like peptide-1/glucagon receptor (GLP - 1/GCGR) dual agonist, has shown marked efficacy in glycemic control, weight loss, and metabolic improvement in adults. However, data in adolescents remain limited. This report explores its therapeutic potential in an adolescent with obesity-related type 2 diabetes mellitus (T2DM) and hyperuricemia (HUA). We report the case of a 15-year-

Source
peer_reviewed_research
DOI
10.3389/fendo.2025.1654506
PubMed
41030857
Open original source
2025Animal research

Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.

Content-verified record concerning Mazdutide: "Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis." Abstract excerpt: Cognitive impairment and dementia are highly associated with obesity and type 2 diabetes mellitus (T2DM). Recent studies have demonstrated that GLP-1 receptor agonists can improve cognitive function through brain activation in patients with T2DM, compared to other oral glucose-lowering drugs. Mazdutide, a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR

Source
peer_reviewed_research
DOI
10.1016/j.ebiom.2025.105791
PubMed
40479843
Open original source
2026Animal research

Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.

Content-verified record concerning Mazdutide: "Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation." Abstract excerpt: Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disorder globally. Mazdutide has shown clinical benefits in weight management and metabolic regulation, indicating its potential as a therapeutic agent for MASLD. This study aimed to investigate the efficacy and mechanism of action of Mazdutide against early-stage MASLD. Methods: A MASL

Source
peer_reviewed_research
DOI
10.3390/ph19030371
PubMed
41901218
Open original source
2026Animal research

Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.

Content-verified record concerning Mazdutide: "Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes." Abstract excerpt: Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes. While its clinical efficacy is increasingly recognized, the intellectual property framework that underpins its development and long-term positioning has not been systematically examined. This review present

Source
peer_reviewed_research
DOI
10.1080/13543776.2026.2645812
PubMed
41820018
Open original source
2026Insufficient evidence

Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Content-verified record concerning Mazdutide: "Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis." Abstract excerpt: To assess the effects of mazdutide on body weight, HbA1c, metabolic outcomes, and adverse events in adults with overweight/obesity and/or type 2 diabetes (T2D). This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, a

Source
systematic_review_or_meta_analysis
DOI
10.1111/dom.71058
PubMed
42410325
Open original source
2026Insufficient evidence

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.

Content-verified record concerning Mazdutide: "Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1001/jama.2026.8427
PubMed
42251596
Open original source
2025Insufficient evidence

Once-Weekly Mazdutide in Obesity or Overweight. Reply.

Content-verified record concerning Mazdutide: "Once-Weekly Mazdutide in Obesity or Overweight. Reply." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1056/nejmc2509841
PubMed
40929642
Open original source
2026Insufficient evidence

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Content-verified record concerning Mazdutide: "Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes." Abstract excerpt: Mazdutide is a once-weekly glucagon and glucagon-like peptide 1 receptor dual agonist developed for the treatment of type 2 diabetes (T2D) 1 . Here we report on a randomized phase III trial assessing the efficacy and safety of mazdutide, compared with dulaglutide, in participants with T2D who were also treated with background oral anti-diabetic drugs. In this study, 731 participants with T2D were

Source
peer_reviewed_research
DOI
10.1038/s41586-025-10031-z
PubMed
41407860
Open original source
Insufficient evidence

Efficacy and Safety of Mazdutide in Adults with Obesity or Overweight, With or Without Diabetes: A Bayesian Network Meta-Analysis

Source reference associated with Mazdutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.21203/rs.3.rs-9477385/v1
Open original source
Insufficient evidence

Mazdutide Ameliorates Non-Alcoholic Fatty Liver Disease by Modulating Endoplasmic Reticulum Stress

Source reference associated with Mazdutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.20944/preprints202601.1103.v1
Open original source
Insufficient evidence

Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

Source reference associated with Mazdutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.12688/f1000research.186694.1
Open original source
Insufficient evidence

Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

Source reference associated with Mazdutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.12688/f1000research.186847.1
Open original source
Insufficient evidence

Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis

Source reference associated with Mazdutide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.21203/rs.3.rs-7884657/v1
Open original source
2025Insufficient evidence

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

Direct clinical study in its enrolled adult population; does not establish outcomes beyond its design.

Source
peer_reviewed_research
DOI
10.1056/nejmoa2411528
PubMed
40421736
Open original source
2026Insufficient evidence

Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Content-verified record concerning Mazdutide: "Mazdutide versus placebo in Chinese adults with type 2 diabetes." Abstract excerpt: Despite advances in type 2 diabetes (T2D) management, unmet needs remain for therapies that effectively control hyperglycaemia while addressing comorbid metabolic disorders 1,2 . Here we assessed the efficacy and safety of the dual glucagon receptor (GCGR)/glucagon-like peptide-1 receptor (GLP-1R) agonist mazdutide monotherapy versus placebo in Chinese adults with T2D controlled inadequately with

Source
peer_reviewed_research
DOI
10.1038/s41586-025-10026-w
PubMed
41407859
Open original source
2025Insufficient evidence

Mazdutide: First Approval.

Content-verified record concerning Mazdutide: "Mazdutide: First Approval." Abstract excerpt: Mazdutide (Xinermei ® ) is a dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist being developed by Eli Lilly and Company along with Innovent Biologics for use in weight management in adults with obesity or overweight and for the treatment of type 2 diabetes (T2D). In June 2025, mazdutide received its first approval, in China, for use (in combination with

Source
systematic_review_or_meta_analysis
DOI
10.1007/s40265-025-02249-y
PubMed
41028652
Open original source
2024Insufficient evidence

Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.

Content-verified record concerning Mazdutide: "Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials." Abstract excerpt: Overweight and obesity are increasing global public health problems. Mazdutide is a new dual agonist drug that can potentially reduce weight and blood glucose levels simultaneously. However, the synthesis of evidence on the efficacy and safety of this drug is scarce. Therefore, this study aimed to synthesize evidence on the efficacy and safety of Mazdutide compared to placebo on weight reduction a

Source
systematic_review_or_meta_analysis
DOI
10.3389/fendo.2024.1309118
PubMed
38440786
Open original source
2026Insufficient evidence

Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.

Content-verified record concerning Mazdutide: "Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes." (identity confirmed; no abstract text available to excerpt.)

Source
peer_reviewed_research
DOI
10.1001/jama.2026.10443
PubMed
42251768
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C207H317N45O65
Molecular weight (Da)
4476
SMILES
CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC8=CNC=N8)N
InChI
InChI=1S/C207H317N45O65/c1-116(2)93-144(189(295)230-138(70-76-168(271)272)179(285)221-107-162(264)219-109-166(268)252-86-46-57-157(252)201(307)245-154(110-253)181(287)220-106-159(213)261)234-190(296)145(94-117(3)4)236-194(300)151(100-127-104-218-133-52-37-36-51-131(127)133)240-188(294)142(73-79-171(277)278)233-202(308)174(119(7)8)249-197(303)149(96-123-47-30-28-31-48-123)238-187(293)141(72-78-170(275)276)231-183(289)135(56-41-45-83-215-164(266)113-316-91-90-315-88-85-217-165(267)114-317-92-89-314-87-84-216-160(262)75-69-143(205(311)312)225-161(263)58-34-26-24-22-20-18-16-14-15-17-19-21-23-25-27-35-59-167(269)270)226-177(283)120(9)224-182(288)134(53-38-42-80-208)227-184(290)136(54-39-43-81-209)228-186(292)140(71-77-169(273)274)232-195(301)152(102-172(279)280)241-191(297)146(95-118(5)6)235-192(298)147(98-125-60-64-129(258)65-61-125)237-185(291)137(55-40-44-82-210)229-199(305)155(111-254)244-193(299)148(99-126-62-66-130(259)67-63-126)239-196(302)153(103-173(281)282)242-200(306)156(112-255)246-204(310)176(122(11)257)250-198(304)150(97-124-49-32-29-33-50-124)243-203(309)175(121(10)256)248-163(265)108-222-180(286)139(68-74-158(212)260)247-206(313)207(12,13)251-178(284)132(211)101-128-105-214-115-223-128/h28-33,36-37,47-52,60-67,104-105,115-122,132,134-157,174-176,218,253-259H,14-27,34-35,38-46,53-59,68-103,106-114,208-211H2,1-13H3,(H2,212,260)(H2,213,261)(H,214,223)(H,215,266)(H,216,262)(H,217,267)(H,219,264)(H,220,287)(H,221,285)(H,222,286)(H,224,288)(H,225,263)(H,226,283)(H,227,290)(H,228,292)(H,229,305)(H,230,295)(H,231,289)(H,232,301)(H,233,308)(H,234,296)(H,235,298)(H,236,300)(H,237,291)(H,238,293)(H,239,302)(H,240,294)(H,241,297)(H,242,306)(H,243,309)(H,244,299)(H,245,307)(H,246,310)(H,247,313)(H,248,265)(H,249,303)(H,250,304)(H,251,284)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,311,312)/t120-,121+,122+,132-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,174-,175-,176-/m0/s1
InChIKey
XRBYWQZGSZWYEJ-HMQIFOERSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 2022 · study · Temporal status not established

    Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

    peer_reviewed_research

  2. 2023 · study · Temporal status not established

    A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

    peer_reviewed_research

  3. 2024 · study · Temporal status not established

    Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

    peer_reviewed_research

  4. 2024 · study · Temporal status not established

    Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.

    peer_reviewed_research

  5. 2024 · study · Temporal status not established

    Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.

    systematic_review_or_meta_analysis

  6. 2025 · study · Temporal status not established

    Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.

    peer_reviewed_research

  7. 2025 · study · Temporal status not established

    Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.

    peer_reviewed_research

  8. 2025 · study · Temporal status not established

    Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.

    peer_reviewed_research

  9. 2025 · study · Temporal status not established

    Once-Weekly Mazdutide in Obesity or Overweight. Reply.

    peer_reviewed_research

  10. 2025 · study · Temporal status not established

    Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.

    peer_reviewed_research

  11. 2025 · study · Temporal status not established

    Mazdutide: First Approval.

    systematic_review_or_meta_analysis

  12. 2026 · study · Temporal status not established

    Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.

    peer_reviewed_research

  13. 2026 · study · Temporal status not established

    Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial.

    peer_reviewed_research

  14. 2026 · study · Temporal status not established

    Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

    peer_reviewed_research

  15. 2026 · study · Temporal status not established

    Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

    peer_reviewed_research

  16. 2026 · study · Temporal status not established

    Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.

    peer_reviewed_research

  17. 2026 · study · Temporal status not established

    Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.

    peer_reviewed_research

  18. 2026 · study · Temporal status not established

    Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.

    peer_reviewed_research

  19. 2026 · study · Temporal status not established

    Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

    systematic_review_or_meta_analysis

  20. 2026 · study · Temporal status not established

    Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.

    peer_reviewed_research

  21. 2026 · study · Temporal status not established

    Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

    peer_reviewed_research

  22. 2026 · study · Temporal status not established

    Mazdutide versus placebo in Chinese adults with type 2 diabetes.

    peer_reviewed_research

  23. 2026 · study · Temporal status not established

    Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.

    peer_reviewed_research

  24. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    China — NMPA

  25. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    United States — FDA

  26. Date unavailable · study · Temporal status not established

    Efficacy and Safety of Mazdutide in Adults with Obesity or Overweight, With or Without Diabetes: A Bayesian Network Meta-Analysis

    other

  27. Date unavailable · study · Temporal status not established

    Mazdutide Ameliorates Non-Alcoholic Fatty Liver Disease by Modulating Endoplasmic Reticulum Stress

    other

  28. Date unavailable · study · Temporal status not established

    Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    other

  29. Date unavailable · study · Temporal status not established

    Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials

    other

  30. Date unavailable · study · Temporal status not established

    Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis

    other

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 3 represented connections ↓

institution

peer_reviewed_research

represented evidence source

institution

other

represented evidence source

institution

systematic_review_or_meta_analysis

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 13 domain conclusions and 25 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Mazdutide evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

United States — FDA

Regulator: FDA

not_approved

As of: 9/23/2026 · Temporal status not established

FDA Drugs@FDA database

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:47 PM

global evidence atlas

Mazdutide research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

Investigational boundary: Mazdutide is not presented here as FDA-approved, and screening records must not be interpreted as established clinical benefit.

51Discoverable source universe
51Ranked screening records
13Research domains
1Governed published sources

51 matching records · ranked 2026-09-18

Page 1 of 3

#1Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Diabetes, obesity & metabolism · 2026 Oct · PMID 42410325 · DOI 10.1111/dom.71058

Weight loss and obesity · Type 2 diabetes and glycemia · Glucagon and GLP-1 biology · China and regional evidence · Safety and tolerability · Mechanism and pharmacology

Count reconciliation: 51 discoverable source records match the peptide identity query; 51 are retained in this bounded, ranked screening view; 1 belong to the separate governed layer labeled “Governed published sources.” Domain totals overlap because one publication may inform several questions.

Mazdutide evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Mazdutide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 26, 2026.) https://www.worldpeptidefoundation.org/directory/mazdutide

  • AMA / Vancouver

    World Peptide Foundation. Mazdutide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 26, 2026. https://www.worldpeptidefoundation.org/directory/mazdutide